Synergistic effects of gelam honey and fluorouracil (5-FU) on human colorectal cancer HT-29 cells
-
1
Universiti Malaysia Terengganu, Malaysia
-
2
Sultan Zainal Abidin University, Malaysia
Background
Gelam or Melaleuca Honey (GH) is the honey of Apis mellifera from the forest of Melalueca spp in Malaysia. Though it is widely being studied but combinatorial effects with drugs is still lacking. Thus, this study was carried out to determine combinatorial effects of Gelam honey and 5-FU on human colorectal cancer HT-29 cells.
Methods
In this study, MTT assay was done to determine the cytotoxic dose. Cells membrane changes was observed in AO/PI assay. Early event of apoptosis detection were done by annexin-v FITC and mitochondria membrane potential. TUNEL assay was performed to examine the fragmented DNA.
Results
The results for MTT assay showed that the IC50 for gelam honey and 5-FU alone were 36.2 mg/ml and 15.5 µg/ml. Meanwhile, the IC50 of combination treatment was 13.2 mg/ml for gelam honey. The combination index was < 1 suggesting the synergism. Early event of apoptosis was occurred in all treatment groups but with different percentage. Combinatorial treatment in apoptosis detection assay showed the highest percentage of apoptotic cells among other treatment groups.
Conclusion
In conclusion, combinatorial treatment of gelam honey and 5-FU may be an effective chemotherapy strategy in fighting colon cancer cells.
Keywords:
Gelam honey,
Fluorouracil,
Apoptosis,
cell dealth,
Synergistic
Conference:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019.
Presentation Type:
Poster Presentation
Topic:
Cancer
Citation:
Tuan Johari
S,
Hashim
F,
Wan Ismail
W and
Ali
A
(2019). Synergistic effects of gelam honey and fluorouracil (5-FU) on human colorectal cancer HT-29 cells.
Front. Pharmacol.
Conference Abstract:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”.
doi: 10.3389/conf.fphar.2018.63.00070
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
30 Sep 2018;
Published Online:
17 Jan 2019.
*
Correspondence:
Mr. Syed Ahmad Tajudin Tuan Johari, Universiti Malaysia Terengganu, Kuala Terengganu, Malaysia, syedtajudin85@gmail.com